J Blade

Summary

Country: Spain

Publications

  1. pmc Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
    Natalia Tovar
    Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clinic, Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Haematologica 98:1142-6. 2013
  2. ncbi request reprint Renal, hematologic and infectious complications in multiple myeloma
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Best Pract Res Clin Haematol 18:635-52. 2005
  3. ncbi request reprint High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
    Joan Blade
    Hematology Department, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    Blood 106:3755-9. 2005
  4. ncbi request reprint Bortezomib: a valuable new antineoplastic strategy in multiple myeloma
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Villarroel 170, 08036, Barcelona, Spain
    Acta Oncol 44:440-8. 2005
  5. ncbi request reprint Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation
    Joan Blade
    Hematology Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Haematologica 90:1589. 2005
  6. ncbi request reprint Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Treat Options Oncol 7:237-45. 2006
  7. ncbi request reprint Clinical practice. Monoclonal gammopathy of undetermined significance
    Joan Blade
    Hematology Department, Institut Clinic de Malaties Hematologiques i Oncologiques, Hospital Clinic, Postgraduate School of Hematology Farreras Valenti, Universitat de Barcelona, Barcelona, Spain
    N Engl J Med 355:2765-70. 2006
  8. ncbi request reprint Complications of multiple myeloma
    Joan Blade
    Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    Hematol Oncol Clin North Am 21:1231-46, xi. 2007
  9. doi request reprint Advances in therapy of multiple myeloma
    Joan Blade
    Hematology and Oncology Institute, Hematology Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Curr Opin Oncol 20:697-704. 2008
  10. doi request reprint Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment
    Joan Blade
    Hematology Department, Universitat de Barcelona Hospital Clinic, IDIBAPS Villaroel 170, Barcelona, Spain
    Clin Lymphoma Myeloma 8:352-5. 2008

Detail Information

Publications44

  1. pmc Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
    Natalia Tovar
    Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clinic, Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Haematologica 98:1142-6. 2013
    ..008 and P=0.0001, respectively), likely reflecting the importance of a robust humoral immune response...
  2. ncbi request reprint Renal, hematologic and infectious complications in multiple myeloma
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Best Pract Res Clin Haematol 18:635-52. 2005
    ..The highest risk of infection is within the first 2 months of initiation of therapy as well as in patients with renal failure and in those with relapsed and refractory disease...
  3. ncbi request reprint High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA
    Joan Blade
    Hematology Department, Hospital Clinic, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    Blood 106:3755-9. 2005
    ..9 vs 16.4 months). In conclusion, these results show that HDT intensification, when given to myeloma patients who have responded to the initial chemotherapy, significantly increases the CR rate but has no significant impact on PFS or OS...
  4. ncbi request reprint Bortezomib: a valuable new antineoplastic strategy in multiple myeloma
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Villarroel 170, 08036, Barcelona, Spain
    Acta Oncol 44:440-8. 2005
    ..Ideally, the introduction of bortezomib will result in a significant improvement in the future management of multiple myeloma...
  5. ncbi request reprint Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation
    Joan Blade
    Hematology Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Haematologica 90:1589. 2005
  6. ncbi request reprint Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Treat Options Oncol 7:237-45. 2006
    ..It is recommended that patients with MGUS are monitored annually. Importantly, patients with asymptomatic monoclonal gammopathies must not be treated before the development of overt multiple myeloma...
  7. ncbi request reprint Clinical practice. Monoclonal gammopathy of undetermined significance
    Joan Blade
    Hematology Department, Institut Clinic de Malaties Hematologiques i Oncologiques, Hospital Clinic, Postgraduate School of Hematology Farreras Valenti, Universitat de Barcelona, Barcelona, Spain
    N Engl J Med 355:2765-70. 2006
  8. ncbi request reprint Complications of multiple myeloma
    Joan Blade
    Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    Hematol Oncol Clin North Am 21:1231-46, xi. 2007
    ..This article reviews these various complications connected to multiple myeloma, examining their various causes and possible treatment...
  9. doi request reprint Advances in therapy of multiple myeloma
    Joan Blade
    Hematology and Oncology Institute, Hematology Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Curr Opin Oncol 20:697-704. 2008
    ..To summarize the results of treatment of multiple myeloma in the era of novel agents...
  10. doi request reprint Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment
    Joan Blade
    Hematology Department, Universitat de Barcelona Hospital Clinic, IDIBAPS Villaroel 170, Barcelona, Spain
    Clin Lymphoma Myeloma 8:352-5. 2008
    ..However, patients with impaired renal function were at a slightly increased risk of a drug-related serious adverse event (28% vs. 19% for CrCl < 60 and > or = 60 mL/min, respectively)...
  11. pmc Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations
    Joan Blade
    Hematology Department, Institute of Hematology and Oncology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Clin Oncol 28:690-7. 2010
    ..To provide an overview on smoldering (asymptomatic) multiple myeloma (SMM) including current diagnostic criteria, predictors of progression, pattern of progression, and outcome...
  12. doi request reprint Hematopoietic stem cell transplantation for multiple myeloma beyond 2010
    Joan Blade
    Department of Hematology and Bone Marrow Transplant Unit, Institut of Hematology and Oncology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Blood 115:3655-63. 2010
    ..The development of novel reduced-intensity preparative regimens and peri- and posttransplantation strategies aimed at minimizing graft-versus-host disease, and enhancing the graft-versus-myeloma effect are key issues...
  13. doi request reprint Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome
    Joan Blade
    Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Clin Lymphoma Myeloma Leuk 11:44-9. 2011
    ..To identify patients who might most benefit from this new standard of care, we performed retrospective analyses evaluating the effects of clinically defined, high-risk features on the outcomes with this regimen...
  14. doi request reprint Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach
    Joan Blade
    Servei d Hematologia, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Clin Oncol 29:3805-12. 2011
    ..Experimental studies on the mechanisms of myeloma cell adhesion, myeloma growth at extramedullary sites, and drug sensitivity are priorities for this area of continuing therapeutic challenge...
  15. ncbi request reprint Autologous transplantation in multiple myeloma
    Joan Blade
    Hematology Department, Institut of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Haematologica 91:1157. 2006
  16. ncbi request reprint Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance
    Joan Blade
    Institute of Hematology and Oncology, Farreras Valentí Postgraduate School of Hematology, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Br J Haematol 117:387-9. 2002
    ..The actuarial probability of malignant transformation in patients with increased IL-6 and TNF-alpha was not significantly higher than in those with normal values...
  17. ncbi request reprint Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients
    J Blade
    Spanish Cooperative Group for Hematological Malignancies Treatment PETHEMA, Spanish Society of Hematology Institut de Investigacions Biomèdiques August Pi i Sunyer Hospital Clínico Barcelona Spain
    Hematol J 2:272-8. 2001
    ..We present the long-term outcome of 914 patients from two randomized trials comparing three different dose intensity regimens...
  18. ncbi request reprint Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas
    J Blade
    Institute of Haematology and Oncology, Department of Haematology, Postgraduate School of Haematology Farreras Valenti, Barcelona, Spain
    Br J Haematol 113:422-4. 2001
    ..This data suggests that the mechanism of action and effectiveness of thalidomide might depend on the site of the tumour cells...
  19. doi request reprint Multiple myeloma
    J Blade
    Hematology Department, Hematology and Oncology Institute, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ann Oncol 21:vii313-9. 2010
    ..A sequential approach is preferred over combination of multiple agents. Supportive measures include the use of bisphosphonates and erythropoietin according to the updated guidelines...
  20. ncbi request reprint Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
    S Montoto
    Department of Hematology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    Ann Oncol 13:523-30. 2002
    ..These would be useful for selection of high-risk patients for inclusion in trials aimed at determining the effect of new treatment approaches in such patients...
  21. ncbi request reprint High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
    E Nadal
    Hematology Department, BMT Section, Institute of Hemato Oncology, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Bone Marrow Transplant 33:61-4. 2004
    ..Finally, the pretransplant features significantly associated to CR were a low M-protein size (serum </=10 g/l and urine <0.5 g/24 h) (P=0.0003) and a proportion of bone marrow plasma cells of </=5% (P=0.02)...
  22. ncbi request reprint Malignant transformation in IgM monoclonal gammopathy of undetermined significance
    S Montoto
    Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, Department of Hematology and Hematopathology Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Semin Oncol 30:178-81. 2003
    ..Thus, in IgM MGUS the rate of transformation was similar to the risk observed in other MGUS types, the percentage of BMPC and BML being the features significantly associated with evolution into WM...
  23. ncbi request reprint Smoldering multiple myeloma: natural history and recognition of an evolving type
    L Rosinol
    Hematology Department, Institut Clinic de Malalties Hemato Oncologiques, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Br J Haematol 123:631-6. 2003
    ..Fifty-seven per cent of patients that required chemotherapy showed no or minimal response. The median survival from diagnosis and from progression was 8.2 and 3.5 years respectively...
  24. ncbi request reprint Treatment approaches for relapsing and refractory multiple myeloma
    J Blade
    Institute of Hematology Oncology, Department of Hematology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Spain
    Acta Oncol 39:843-7. 2000
    ..In heavily pretreated resistant patients a conservative approach with alternate day prednisone (30 to 50 mg) along with pulse cyclophosphamide (800 to 1,200 mg every 2 to 3 weeks) is recommended...
  25. ncbi request reprint Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
    S Montoto
    Department of Hematology and Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona
    Ann Oncol 15:1484-9. 2004
    ..A new prognostic index specifically addressing FL patients, the Follicular Lymphoma International Prognostic Index (FLIPI), has recently been developed, which might also be useful in patients with progression...
  26. ncbi request reprint Thalidomide in refractory and relapsing multiple myeloma
    J Blade
    Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Semin Oncol 28:588-92. 2001
    ..No decrease in the size of soft tissue plasmacytomas was observed in six patients with extramedullary involvement...
  27. ncbi request reprint Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma
    X Filella
    Department of Clinical Biochemistry Unit for Cancer Research, Hospital Clinic, Barcelona, Catalonia, Spain
    Cytokine 10:993-6. 1998
    ..001 for IL-6 and TNF-alpha at 24 and 48 h). The impaired IL-6 and TNF-alpha production in patients with symptomatic MM is probably due to a tumour-related immunosuppressive status...
  28. doi request reprint Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
    C Fernández de Larrea
    Amyloidosis and Myeloma Unit, Department of Hematology, Servei d Hematologia, Hospital Clinic de Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Bone Marrow Transplant 49:223-7. 2014
    ..048). Extramedullary involvement was frequent (24%), being the highest risk in patients with extramedullary involvement at diagnosis (P=0.001). ..
  29. ncbi request reprint Dramatic improvement of POEMS syndrome following autologous haematopoietic cell transplantation
    M Rovira
    Department of Haematology, BMT Unit, Postgraduate School of Haematology Farreras Valenti, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Br J Haematol 115:373-5. 2001
    ..We believe that this is the first reported case of POEMS syndrome treated with AHCT, a procedure that could be considered in similarly affected patients...
  30. ncbi request reprint Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma
    J M Hernandez
    Department of Haematology, Hospital General de Segovia, Segovia, Spain
    Br J Haematol 127:159-64. 2004
    ..According to these results MP remains as the gold standard for treatment of MM and should be the reference for comparison of new therapeutic approaches involving novel agents...
  31. ncbi request reprint Primary systemic amyloidosis presenting as a colonic stricture: successful treatment with left hemicolectomy followed by autologous hematopoietic stem-cell transplantation: report of a case
    S Rives
    Institut Clinic de Malalties Hemato Oncologiques, Department of Hematology and Postgraduate School of Hematology Farreras Valenti, Barcelona, Spain
    Dis Colon Rectum 45:1263-6. 2002
    ..The clinical manifestations and differential diagnosis of gastrointestinal involvement of primary systemic amyloidosis, as well as its current treatment, are discussed...
  32. doi request reprint Pathogenesis and progression of monoclonal gammopathy of undetermined significance
    J Blade
    Department of Hematology, Institut of Hematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Leukemia 22:1651-7. 2008
    ..It is recommended to follow these patients, particularly those with high risk of progression, annually to detect MM before complications, such as renal failure or extensive skeletal, involvement occur...
  33. ncbi request reprint Henoch-Schönlein IgA glomerulonephritis complicating myeloma kidneys: case report
    P Arrizabalaga
    Service of Nephrology, Hospital Clinic, Biomedical Investigation Institute August Pi i Sunyer, C Villarroel 170, 08036, Barcelona, Spain
    Ann Hematol 82:526-8. 2003
    ..This case suggests that mesangial IgA deposition should be considered within the spectrum of consequent glomerular lesion-associated chemotherapy occurring in multiple myeloma...
  34. ncbi request reprint Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases
    R Garcia-Sanz
    Department of Haematology, University Hospital of Salamanca, Paseo de San Vicente, Salamanca, Spain
    Br J Haematol 115:575-82. 2001
    ....
  35. doi request reprint Prognostic factors for multiple myeloma in the era of novel agents
    J Blade
    Institut of Hematology and Oncology, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain
    Ann Oncol 19:vii117-20. 2008
  36. ncbi request reprint Bladder involvement of diffuse large B-cell lymphoma diagnosed by a cytological study of the urine
    M Jiménez-Hernández
    Department of Hematology, Instituto de Investigaciones Biomedicas August Pi i Sunyer, Hospital Clinic, Villarroel, Barcelona, Spain
    Leuk Lymphoma 43:187-9. 2002
    ..This case emphasizes the interest of cytological studies of the urine in cases with suspected bladder involvement by lymphoma...
  37. doi request reprint Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
    C Fernández de Larrea
    Amyloidosis and Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain
    Leukemia 27:780-91. 2013
    ..Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL...
  38. pmc Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents
    Carlos Fernández de Larrea
    Departments of Hematology, Servei d Hematologia, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 96:171-3. 2011
    ..This difference could be due to a higher antitumor effect associated with the use of novel drugs, a stronger immune reconstitution, or both...
  39. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  40. ncbi request reprint Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute LG102, 44 Binney Street, Boston, MA 02115, USA
    Blood 107:3442-6. 2006
    ....
  41. ncbi request reprint The future role of thalidomide in multiple myeloma
    Mario Boccadoro
    Divisione di Ematologia, Ospedale Molinette, Torino, Italy
    Acta Haematol 114:18-22. 2005
    ..The workshop acknowledged the problems associated with designing a phase III study, and it is clear that many areas need to be addressed in the use of thalidomide for the treatment of multiple myeloma...
  42. ncbi request reprint Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma
    Juan Jose Lahuerta
    Spanish Stem Cell Transplantation Group GETH, Spanish Society of Hematology, Madrid
    Leuk Lymphoma 43:67-74. 2002
    ..However, the better response rates associated with the favorable tendency in outcome achieved with BUMEL, continue to justify further prospective studies...
  43. ncbi request reprint Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wihelminenspital, Montleartstrasse 37, A 1171 Vienna, Austria
    Hematol J 3:121-30. 2002
    ..Epoetin treatment should be discontinued if there is no response to the increased dosage, or hemoglobin >14 g/dl. Treatment should resume for patients who exceed 14 g/dl, at a reduced dosage, if their hemoglobin falls below 12 g/dl...
  44. doi request reprint Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....